FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN

oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]

AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 22 days

FDA advisory panel rejects camizestrant after SERENA‑6 results / 29 days

VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days

New drug doubles one-year survival in metastatic pancreatic cancer / 6 wks

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 44 hrs

Common asthma drug may overcome immunotherapy resistance in cancers / 11 days

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days